Company Profile
NextCure Stock Price, News & Catalysts
- Ticker:
- NXTC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.71 USD (-6.09%)
Close
Last updated: August 17, 2026
12.3M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, NXTC closed down 6.09% at $7.71. No new same-company headline was identified in the current news window.
Company overview
Oncology Drug Development
NextCure develops novel therapies for cancer, with a pipeline that includes antibody-drug conjugates and immune-modulating approaches.
SIM0505
SIM0505 is an antibody-drug conjugate targeting cadherin-6 and carrying a topoisomerase-1 inhibitor payload. It is being evaluated in tumors with elevated CDH6 expression, including platinum-resistant ovarian cancer.
LNCB74
LNCB74 is a separate Phase 1 oncology candidate undergoing dose escalation, providing NextCure with a second clinical-stage program.
Future catalysts
- Phase 1 dose-escalation data for SIM0505 at ASCO 2026.
- Phase 1 dose-escalation update for LNCB74 in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of NextCure (NXTC)?
NextCure (NXTC) most recently closed at 7.71 USD, a -6.09% move versus the previous session.
What is the market cap of NextCure (NXTC)?
NextCure currently has a market capitalization of 12.3M USD on BioPharmSignal.
What does NextCure do?
Oncology Drug Development NextCure develops novel therapies for cancer, with a pipeline that includes antibody-drug conjugates and immune-modulating approaches. SIM0505 SIM0505 is an antibody-drug conjugate targeting cadherin-6 and carrying a topoisomerase-1 inhibitor payload. It is being evaluated in tumors with elevated CDH6 expression, including...
On which exchange is NXTC stock listed?
NextCure (NXTC) is associated with NASDAQ, United States, Biopharma.
What is Oncology?
Oncology Drug Development NextCure develops novel therapies for cancer, with a pipeline that includes antibody-drug conjugates and immune-modulating approaches.
Which conditions is NextCure targeting with Oncology?
NextCure is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does NextCure describe recent progress with Oncology?
Phase 1 dose-escalation data for SIM0505 at ASCO 2026. Phase 1 dose-escalation update for LNCB74 in the second half of 2026.
What is Drug?
Oncology Drug Development NextCure develops novel therapies for cancer, with a pipeline that includes antibody-drug conjugates and immune-modulating approaches.